Nanjing Hicin Pharmaceutical Co (SZSE:300584) 3-Year EBITDA Growth Rate : -0.20% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nanjing Hicin Pharmaceutical Co 3-Year EBITDA Growth Rate?

Nanjing Hicin Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.15.

During the past 12 months, Nanjing Hicin Pharmaceutical Co's average EBITDA Per Share Growth Rate was 37.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -0.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -3.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 8.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nanjing Hicin Pharmaceutical Co was 47.50% per year. The lowest was -17.10% per year. And the median was 12.05% per year.

Competitive Comparison of Nanjing Hicin Pharmaceutical Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing Hicin Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanjing Hicin Pharmaceutical Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanjing Hicin Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Nanjing Hicin Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.

Nanjing Hicin Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Nanjing Hicin Pharmaceutical Co (SZSE:300584) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Nanjing Hicin Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Nanjing Hicin Pharmaceutical Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing Hicin Pharmaceutical Co (SZSE:300584) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing Hicin Pharmaceutical Co Ltd (SZSE:300584) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

Heng Road 1, Nanjing Economic and Technological Development Zone, Jiangsu Province, Nanjing, CHN, 210009

Website

http://www.hicin.cn

Nanjing Hicin Pharmaceutical Co Ltd is a China-based company engaged in producing pharmaceutical preparations. In addition, it is also involved in manufacturing synthetic chemicals, conducting new drug research and development as well as technical transferring. The company produces series of the medicines such as antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for the cardio-cerebral system and immuno-modulate agents. The active pharmaceutical ingredients, omeprazole sodium for injection, cefepime hydrochloride for Injection and lansoprazole tablets are exported by the firm into South-Asian countries, South-American countries and European countries.

Executives

Cao Yu Ping	Directors, executives
Yan Mei Qiang	Directors, executives
Jiang Xiang Ming	Executives
Gu Hai	Independent director

Nanjing Hicin Pharmaceutical Co (SZSE:300584) Headlines

No Headlines